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ABSTRACT 
 
The renal basic amino acid metabolism often differs in rodents, strict carnivore, and omnivore 
species. Given the pivotal role of L-arginine and L-ornithine in several metabolic pathways 
and the fact that the dog is closely related to humain being also an omnivore, we tested 
whether L-arginine metabolism and L-ornithine catabolism take place in the dog kidney. We 
examined the metabolic of L-arginine in dog cortical tubules to integrate local L-arginine 
metabolism into a general physiological and metabolic framework. To achieve these goals, we 
first ascertained the protein expression of relevant enzymes identified by Western blotting. L-
arginine catabolism was studied in suspensions of canine cortical proximal tubules, medullary 
thick ascending limbs, and papillary collecting ducts either incubated without exogenous L-
arginine being added (small endogenous quantities) or incubated with L-arginine being added 
in supraphysiological amounts (2 mmol/L with or without the presence of alternative metabolic 
substrates, 2 mmol/L L-glutamine, or lactate). The results revealed that dog kidneys consumed 
L-citrulline and released L-arginine and L-ornithine. Argininosuccinate synthetase and lyase, 
arginase II, and ornithine aminotransferase were detected in the renal cortex. Arginase II 
activity was found in a suspension of proximal tubules by measuring the amounts of urea and 
L-ornithine produced. A fraction of this L-ornithine was further partially metabolized through 
the intramitochondrial ornithine aminotransferase pathway, leading to changes in L-glutamate, 
glucose, L-alanine, and ammonia metabolism without L-proline accumulation. Medullary thick 
ascending limbs expressed a very low arginase activity whereas papillary collecting ducts did 
not. In conclusion, the dog kidney produces L-arginine. Part of this L-arginine is further 
catabolized by arginase II, suggesting that its physiological role was to produce L-ornithine for 
the body. 
 
 - 3 - 
Key words: L-citrulline, L-arginine, L-ornithine, dog, proximal convoluted tubules, 
argininosuccinate lyase, argininosuccinate synthetase, arginase type II, ornithine 
aminotransferase, plasma, Western blot. 
 - 4 - 
INTRODUCTION 
 
The mammalian kidney expresses several enzymes involved in L-arginine anabolism and 
catabolism [1,2]. The anabolic enzymes, namely, argininosuccinate synthetase (ASS, Enzyme 
Commission [EC] 6.3.4.5) and argininosuccinate lyase (ASL, EC 4.3.2.1), convert L-citrulline 
in the presence of L-aspartate and adenosine triphosphate (ATP) into L-arginine and fumarate 
within 2 steps (Fig. 1). The catalytic, physical, and chemical properties of these enzymes as 
well as the enzymatic mechanisms have been analyzed in details in kidneys of different species 
including guinea pig and rat [3]. The contribution of the kidney in L-arginine synthesis was 
demonstrated by injecting L-[ureido-14C] L-citrulline to rats and by measuring the 
incorporation of labeled L-arginine into proteins [4]. In rats with intact kidneys, labeled 
proteins were detected in kidneys, muscle, liver, and brain, whereas, in rats with ligated renal 
pedicles, the incorporation of radioactivity into proteins was dramatically lowered [4]. In the 
same way, experiments performed on isolated perfused rat kidney showed a progressive 
reduction in perfusate L-[ureido-14C] L-citrulline associated with a progressive increase in L-
[guanidino-14C] L-arginine [5]. Furthermore, the expression of ASS and ASL genes based on 
the measurement of their transcripts, proteins, and enzyme activities has been reported during 
development of rat [6,7] and mouse [8] kidneys as well as in adult rat [9-11] and mouse [12] 
kidneys. Physiological studies clearly demonstrated the renal synthesis of L-arginine by 
quantitating arterial and renal venous concentrations of L-citrulline and L-arginine. A net renal 
uptake of L-citrulline from the blood was closely matched by a release of L-arginine into the 
bloodstream of control rats [13], rats with 5/6 nephrectomy [14], mongrel dogs [15], mice 
[16,17], and patients with chronic renal failure [18]. Within the mammalian kidney, ASS and 
ASL genes are constantly expressed in the cortex, and in a lesser extent, in the outer stripe of 
the outer medulla [19,20]. More detailed studies revealed that these enzymes are localized in 
the proximal tubule (PT) and exhibit their highest activity in the proximal convoluted tubule 
(PCT) [8,21-23]. 
 
In the kidney, L-arginine catabolism is controlled by several enzymes including arginase type 
II (AII, EC 3.5.3.1), which hydrolyses L-arginine into urea and L-ornithine, and arginine-
glycine amidinotransferase (GAT, EC 2.1.4.1), which metabolizes L-arginine and L-glycine 
into guanidinoacetic acid and L-ornithine (Fig. 1). Although other enzymes metabolizing L-
arginine are expressed in the kidney, our attention is restricted to AII and GAT. The expression 
of an arginase gene in the kidney has been reported in rats [24], rabbits [25], mice [26,27], 
dogs [24,28,29], humans [24,27,30], and other species [24,28,31] (for review, see also [2,31]). 
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In the dog kidney, the arginase activity is almost exclusively confined in the cortex compared 
with the other renal zones [28]. Within the dog cortex, arginase activity was twice higher in the 
superficial cortex than that in the deep cortex, whereas it was about 40-fold lower in the outer 
stripe of the outer medulla. In contrast, the red and white medullae were devoid of an arginase 
activity [28]. In dogs, the renal arginase isoform strongly differs from that of the liver [24]. In 
another report, it was concluded that the dog kidney is capable of de novo urea synthesis, 
suggesting the presence of an arginase activity [32]. Given the high cellular heterogeneity in 
the kidney, the enzyme exhibits a typical distribution pattern of expression along the nephron. 
The expression of AII is constantly found in the cortical and outer medullary proximal straight 
tubules and in other nephron segments that varied from a species to another species [19,23,33-
35]. The expression of GAT has been reported in kidneys of several rodents, dogs [36], and 
humans [37]. Arginine-glycine amidinotransferase is found in the renal cortex and, in a lesser 
extent, in the outer stripe of the outer medulla. Detailed studies based on the use of 
immunological technology and microdissection of the nephron revealed that GAT is expressed 
only in the PT with the highest activity in the PCT [38,39]. 
 
In several species, given that the proximal tubular cells express the enzymes cited above, the 
steady-state tissular concentration of L-arginine may thus be finely regulated through changes 
in these opposite fluxes with consequences for the local metabolism of L-arginine and local 
urea production. In addition, the endogenous production of L-ornithine by AII and GAT as 
well as the cellular uptake of L-ornithine provide L-ornithine for ornithine decarboxylase 
(ODC, EC 4.1.1.17), the rate limiting enzyme of the polyamine pathway, and for ornithine 
aminotransferase (OAT, EC 2.6.1.13), the key enzyme involved in L-glutamate, L-glutamine, 
and L-proline synthesis. 
 
An abundant literature supports that the renal metabolism of L-arginine and L-ornithine varied 
from one species to another species. For example, strict canivores such as cats are unable to 
produce sufficient amounts of L-citrulline to support their metabolic needs in L-arginine [21]. 
In contrast, dogs are not strict carnivores and can eat less meat than cats. As omnivores, dog 
metabolism does not strongly differ from that of humans and might constitute an excellent 
experimental model when human kidneys are not available. At present, L-arginine metabolism 
is poorly studied in dog kidneys. This statement is supported by the lack of data concerning the 
renal expression of ASS and ASL genes and the precise identification of the segments of the 
dog nephron that are involved in L-arginine anabolism and catabolism as well as L-ornithine 
metabolism. In addition, the metabolic consequences of the expression of ASS, ASL, AII, and 
GAT on the other metabolic pathways have never been examined in the kidney. 
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Therefore, we investigated in vivo L-arginine anabolism in the dog kidney by measuring the 
concentration of plasma amino acids in the renal vein and abdominal aorta and calculating the 
renal balance of each L-amino acid. In addition, the expression of ASS and ASL was tested in 
the different subcellular compartment of the renal dog cortex by Western blot analyses. To 
determine which nephron segments express AII, L-arginine catabolism was analyzed in 3 
representative segments of the dog nephron ; and the production of urea and L-ornithine was 
determined. The metabolic fate of L-ornithine produced by AII and the use of L-arginine as a 
potential metabolic substrate when omitted from the incubating medium (no L-arginine added), 
presented in subphysiological (10-50 µmol/L) and physiological quantities (100-200 µmol/L), 
or when added in supraphysiological amounts (0.5-2 moml/L) as well as the competition of L-
arginine with L-glutamine or lactate oxidation at both levels are useful information to integrate 
the presence of AII activity into a general physiological and metabolic framework. 
 
Our results showed that, in vivo, the dog kidney extracted L-citrulline from the arterial blood 
and released equimolar amounts of L-arginine in the blood of the renal vein. The functionality 
of this pathway was confirmed by detecting significant amounts of ASS and ASL proteins in 
the cortex of dog kidney. Dog PTs efficiently hydrolyzed L-arginine to produce an 
accumulation of urea and L-ornithine. The functionality of this pathway was supported by the 
mitochondrial expression of AII in the dog cortex. A small fraction of L-ornithine derived 
from L-arginine was further converted into L-glutamate by the mitochondrial OAT. The 
accumulation of L-ornithine in vitro suggested that the release of L-ornithine observed in the 
renal vein might originate in part from L-arginine. In a general physiological and metabolic 
framework, (1) dogs are not auxotroph for L-arginine because L-citrulline is available, (2) L-
arginine metabolism interacted with L-glutamine catabolism, and (3) L-arginine was not a 
major gluconeogenic substrate in isolated dog PTs. The medullary thick ascending limbs 
(MTALs) hydrolysed L-arginine at a very low rate, and the collecting duct did not catabolize 
L-arginine significantly.  
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2. MATERIAL  and  METHODS 
 
2.1. Animals 
Six mongrel dogs used for metabolic studies were anesthetized with 30 mg Nembutal (Clin 
Midy, Paris, France) per kilogram body weight, (BW). Twenty milliliters of 20% mannitol was 
injected intravenously to open the lumen of renal tubules. Five beagle dogs of approximately 
18 kilogram BW were used for Western blot and plasma amino acid analyses (a gift from 
Ecole Vétérinaire, Marcy l’Etoile, France). Dogs were anesthetized by injecting intravenously 
20 mg sodium pentobarbital per kilogram BW (Nembutal 18%, Clin Midy, Paris, France). Six-
week-old female Sprague Dawley rats from Charles Rivers Laboratories (L'Arbresle sur Orge, 
France) had free access to tap water and standard laboratory food (Souffirat, 20% protein, 
Genthon S.A., France) and were housed in a room maintained at 20°C with a 12-hour 
light/dark cycle. The rats were anaesthetized by injecting intraperitoneally 0.1 mL/100 g BW 
sodium pentobarbital (Nembutal 6%, Clin Midy). Mongrel dogs were cared for in accordance 
with the principles and guidelines of the Canadian Council on Animal Care. Rat and beagle 
dogs care complied with French regulations for the protection of animals used for experimental 
and other scientific purposes and with European Community regulations. The author is 
authorised (no. 69-33) to use animals for these experiments. 
 
2.2. Amino acid determination in arterial and renal venous blood 
Blood was collected in the renal vein of the left kidney and the abdominal aorta of 5 beagle 
dogs with a 23-gauge needle (Terumo, Neolus, Guyancourt, France) mounted on a 10 mL 
syringe (Terumo) heparinized (Heparin, Roche Diagnostics, Meylan, France) 1 day before the 
experiment and dried at room temperature. The tip of the needle was curved, pushed into the 
initial portion of the renal vein near the exit of the kidney, pointed toward the kidney, and 
pushed in the hilus to prevent blood backward surge from vena cava and spermatic vein. Four 
to five milliliters of blood were collected slowly and regularly at a maximum rate of 5 
mL/min, transferred into lithium heparinized Vacutainer tubes, and maintained at 4°C. Blood 
was centrifuged at 11 700 g for 15 minutes at 4°C to collect the plasma. Two-hundred 
microliters of nonhemolyzed plasma were deproteinized by adding 20 µL of 30% 
sulfosalicylic acid, vortexed, put on ice for 60 minutes, and centrifuged at 11 700 g for 15 min 
at 4°C. The supernatant was collected and frozen at -80°C until amino acid analysis was 
carried out. 
 
Plasma amino acids were determined in sulfosalicylic deproteinized samples by ion-exchange 
chromatography using a Jeol AminoTac amino acid analyser according to the manufacturer's 
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methodology. Before analysis, samples were half-diluted with a dilution buffer (Jeol) 
containing 2 amino acid standards: D-glucosaminic acid and 2-aminoethyl cysteine. Plasma 
from the National Quality Control for amino acid analysis was regularly used to check our 
method. 
 
2.3. Preparation of tubule suspension for metabolic studies 
The kidneys were removed, decapsulated, and placed in a modified ice-cold Krebs-Henseleit 
saline (KHS) composed of 112.7 mmol/L NaCl, 3.3 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2 
mmol/L MgSO4, 0.5 mmol/L CaCl2, 50 mmol/L mannitol, 25 mmol/L NaHCO3 (pH 7.4) at 
37°C and osmolality at 350 mosm/kg. The superficial cortex, the inner stripe of the outer 
medulla, and the papilla were dissected with scissors. The tissues were then sliced using a 
Stadie-Riggs microtome to obtain slices of homogenous thickness. Slices were washed 3 times 
with ice-cold KHS to remove cell debris. Cortical tubules (> 85% PTs), MTALs, and papillary 
collecting ducts (PCDs) were prepared from relevant tissue by collagenase digestion as 
previously described [40]. After the digestion, the final suspension adjusted to 60 mg wet 
weight per milliliter was kept at 4°C in standard KHS fully gassed with 5% CO2 + 95% O2 
until utilization [40]. Aliquots of the tubule suspensions were dried to obtain the tissue dry 
weight after subtraction of the weight due to salts and mannitol contained in KHS. 
 
2.4. Metabolic behaviour : substrates utilization and metabolites production 
The tubule suspension (30 mg wet weight per flask) was incubated at 37°C for 30, 60, and 120 
minutes (PTs); 60 and 120 minutes (MTALs); and 120 minutes (PCDs) in 4 mL KHS 
(previouly gassed with 5% CO2 + 95% O2) using 50-mL siliconized Erlenmeyer flask in the 
absence or presence of exogenous substrates (2 mmol/L lactate + 0.2 mmol/L pyruvate or 2 
mmol/L L-glutamine + 0.2 mmol/L L-glutamate for PTs, 2 m mmol/L lactate + 0.2 mmol/L 
pyruvate for MTALs, and 2 mmol/L glucose for PCDs) in absence or presence of 2 mM L-
arginine. For each experimental condition, blanks (T = 0) were prepared at 4°C with the same 
tubular suspension, KHS, and substrates but were immediately deproteinized as described 
below. A 10-fold supraphysiological concentration of exogenous L-arginine was used to 
prevent a rapid depletion of L-arginine during the metabolic incubation and to enhance the 
level and the detection of the metabolites derived from L-arginine catabolism. Furthermore, to 
prove that L-arginine catabolism occured at physiological concentrations of L-arginine in PTs, 
a dose-response curve of urea/L-ornithine production was obtained in 2 experiments designed 
to present : 0, 0.01, 0.025, 0.05, 0.1, 0.2, 0.5, 1, 2, 5, and 10 mmol/L L-arginine to a 
suspension of PTs in the presence of 2 mmol/L lactate + 0.2 mmol/L pyruvate and incubated 
for 30 minutes at 37°C. 
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At the end of the incubation, the content of the flasks was deproteinized with 0.4 mL 20% 
perchloric acid (PCA); and 4.3 mL of the supernatant were neutralized with 0.3 mL 40% KOH. 
The following metabolites were measured enzymatically on the neutralized PCA extract [40, 
41]: lactate, pyruvate, L-glutamine, L-glutamate, α-ketoglutarate, L-aspartate, L-alanine, 
NH4+, glucose, urea, L-arginine. Therefore, all intracellular and extracellular metabolites were 
measured together, allowing to calculate net extraction and production of metabolites 
irrespectively of intracellular concentration or compartmentation. 
 
To know whether L-ornithine was produced by AII during the metabolic incubation, the 
supernatant was analyzed by 2-dimensional thin-layer chromotography as described by Bremer 
et al. [42]. Each plate (cellulose thin-layer plate 10 x 10 cm; Merck Frosst Canada, Kirkland, 
Quebec, Canada) was developed twice in solvant 1 (pyridine/dioxane/25% ammonia/water 
[35; 35; 15; 15, vol/vol]) for 120 minutes, dried, and developed twice in solvant 2 (n-
butanol/acetone/acetic acid/water [35; 35; 7; 23, vol/vol]) for 60 minutes. The plate was 
sprayed with ninhydrin solution and dried. The spot of L-ornithine was identified and cut to 
quantify the amount of L-ornithine by using the ninhydrin colorimetric method [43]. Standard 
solutions of L-ornithine were analyzed in the same time to determine the concentration of L-
ornithine in the samples. In addition, we wanted to prove by another way that the positive 
ninhydrin-reactive substance was L-ornithine. A full high-performance liquid chromatography 
(HPLC) aminogram was performed from the supernatant of PT incubated with 2 mmol/L L-
arginine. Amino acids were measured after phenylisothiocyanate derivatization [44] by 
reverse-phase HPLC (Waters Pico-Tag column, 0.39 X 15 cm, 38°C) using a solvent system 
consisting of 140 mmol/L sodium acetate containing TEA (0.5 mL TEA/L) and 60% aqueous 
CH3CN. Detection at 254 nm allowed quantification, by peak surface comparison with internal 
and external standards, using a Spectra-Physic integrator model SP4270. 
 
2.5. Preparation of cytosolic and mitochondrial fractions by differential centifugation 
The whole renal cortex of one dog and the outer stripe of the outer medulla of female rats 
were dissected at 4°C under a stereomicroscope. The dissected tissue was rapidly immersed in 
a buffer composed of 250 mmol/L sucrose, 10 mmol/L Tris-HCl, and 1 mmol/L Na2EDTA, 
(pH 7.6) homogenized using a motor-driven Potter-Elvehjem glass homogeneizer with a 
loose-fitting Teflon pestle (Bellco Glass, Vineland, NJ) and centrifuged at 600g for 10 
minutes at 4°C to remove cell debris and the nuclear fraction. The supernatant (S1) was 
centrifuged at 12 000g for 15 minutes at 4°C to pellet the mitochondrial fraction. The 
supernatant (S2) was centrifuged at 128 000g for 60 minutes at 4°C (Optima TLA 100.2 
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Ultracentrifuge, Beckman) to obtain proteins of the cytosolic fraction in the supernatant (S3). 
To wash the mitochondria, the pellet was resuspended 3-times in the same buffer and 
centrifuged 12 000g for 15 min at 4°C. The cytosolic fraction was submitted to a speed-vac 
evaporation to concentrate the proteins. Protein concentrations were determined using the 
Bradford protein assay [45]. Cytosolic proteins and purified mitochondria were dissolved in 
Laemmli buffer (62.5 mmol/L Tris-HCl [pH 6.8], 1% sodium dodecyl sulfate [SDS], 10% 
glycerol, 0.1 mol/L dithioerythriol, and bromophenol blue [46]), heated at 95°C for 5 minutes, 
and immediately dipped in a bath maintained at 4°C.  
 
Western blot analyses 
Two hundred-microgram samples of soluble proteins were subjected to 9% SDS-
polyacrylamide gel electrophoresis (PAGE) containing 0.1% SDS applying 6 W per gel 
(14x16 cm). Twenty microliters of a protein ladder (Precision Plus Protein Standards; Bio-
Rad, Marnes la Coquette, France) were also loaded to verify the size of the protein of interest. 
Proteins were transferred to a polyvinylidene difluoride membrane (0.45 µm, Immobilon-P; 
Millipore, St Quentin en Yvelines, France) at 150 mA for 90 minutes. Proteins were 
visualized on the membrane with Ponceau S solution. Immunoblots were washed twice for 15 
minutes in 1x Tris-buffered salt Tween (TBST; 20 mmol/L Tris [pH 7.6], 137 mmol/L NaCl, 
0.1% Tween 20) and immersed twice in a blocking solution consisting of 5% fat-free milk 
powder in 1x TBST for 30 minutes.  
 
Immunoblots were incubated in 5% fat-free milk in 1x TBST with the primary polyclonal 
rabbit antibodies raised against ASS (dilution 1:1000) [47], ASL (dilution 1:1000) [48], OAT 
(CovalAb, Villeurbanne, France, dilution 1:1000) [49], AII (CovalAb, dilution 1:500) [49], 
aconitase (dilution 1:10000) [50], and the monoclonal mouse antibody raised against the α-
subunit F1-ATP synthase (dilution 1:5000) [49]. The antibodies were incubated separately for 
60 minutes. Afterward, the immunoblot was rinced 3-times for 15 minutes in 1x TBST and 
incubated for 60 minutes with either a peroxidase-conjugated anti-rabbit immunoglobulin G 
(IgG) or a anti-mouse IgG secondary antibody (dilution 1:10000-1:20000) in 5% fat-free milk 
in 1x TBST. The immunoblot was washed 3-times for 15 minutes in 1x TBST and antibody 
binding was revealed using chemiluminescence (ECL) Western blotting kit. The ECL 
detection was performed using Kodak X-MAT films. Low-exposure film was scanned using 
the ImagerMaster Total Lab version 2.01 program (Pharmacia, Orsay, France). The 
immunoblot was washed 2-times for 15 minutes in 1x TBST and incubated with a new 
antibody. 
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2.7. Chemicals 
Amino acids and substrates were purchased from Sigma Chemical (Montreal, Canada); and 
SDS, sucrose, glycerol, Tween 20, dithioerythriol, phenylmethylsulphonylfluoride, 
benzamidine, ponceau S solution, peroxidase-conjugated anti-rabbit and anti-mouse IgG 
secondary antibodies, X-MAT films were purchased from Sigma (Saint Quentin Fallavier, 
France). Enzymes for enzymatic determinations were from Boehringer (Manheim, Germany). 
 
2.8. Results and statistical analysis 
The plasma levels of amino acids are expressed in micromoles per liter (mean ± SE, n = 5 
dogs). Given that blood was sampled in the aorta (A) and the renal vein (V) of each dog, V-A 
difference was calculated for each amino acid; and where appropriate, statistical differences 
were assessed using the non-parametric Wilcoxon test for paired data at the 95% level 
significance (StatView SE+Gr and StatView 5). 
 
For the metabolic studies, PTs were incubated 30, 60, and 120 minutes. Given that plotting 
metabolic rates of PTs against incubation time revealed linearity up to 60 minutes for PTs, the 
data obtained at 120 minutes were discarded. To calculate the metabolic rate for each 
experimental condition and substrate, the data obtained at 30 minutes were multiplied by 2 and 
a mean value was calculated with the data abtained at 60 minutes. In contrast, for MTALs, we 
used the data obtained at 60 and 120 minutes to calculate a mean production per hour. 
 
In Table 2 and 3, data are presented as micromoles of metabolites extracted (-) or produced (+) 
per gram wet weight and per hour (means ± SE). The data were analyzed using appropriate 2-
ways and 1-way analyses of variance (ANOVA) (SuperANOVA software, Abacus), and a P < 
.05 was accepted as significant. The ANOVA was used to analyze simultaneously all the data 
of each protocol in order to examine statistically: (1) the effect of substrates (none, lactate, L-
glutamine), (2) the effect of cationic amino-acid (none, L-arginine), and (3) the effect of the 
incubation times (0, 30, 60, and 120 minutes). The effect of experimental replication (n = 4 in 
Tables 1 and 2) was found not significant. Only the main effects are reported because the 
interactions found could be explained by obvious mechanisms and could distract the reader 
from the main point of the article. 
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3. RESULTS 
 
3.1. Anabolism of L-arginine in the dog kidney 
This experiment was conducted to know whether the dog kidneys synthesize L-arginine from 
L-citrulline as in other mammals except the carnivores ones [13-18, 21]. This biochemical 
pathway requires the expression of ASS and ASL and the substrates L-citrulline and L-
aspartate. The concentration of plasma amino acids was measured in the renal vein (V) and 
aorta (A); and the renal balance (V-A) that reflects either a production and a release when the 
V-A difference is positive or an extraction and a consumption when the V-A difference is 
negative was calculated for each amino acid. Given that 24 L-amino acids were simultaneously 
detected by HPLC, we present their plasma concentrations in Table 1 and comment briefly on 
the data below.  
 
The plasma concentration of L-citrulline was 16 ± 4 µmol/L higher in the aorta than that in the 
renal vein, indicating a significant uptake of L-citrulline by the kidney (Fig. 2; Wilcoxon, P < 
.005). Concomitantly, the plasma concentration of L-arginine was significantly increased by 22 
± 4 µmol/L in the renal vein compared with that in the aorta and corresponded to de novo L-
arginine production (Fig. 2; Wilcoxon, P < .005). The disappearance in L-citrulline was 
statistically equal to the renal production of L-arginine (Wilcoxon, P = .9593). The results 
prove that the anabolic pathway of L-arginine exists in dog kidneys. Similarly, the plasma 
concentration L-ornithine was 9 ± 2 µmol/L higher in the renal vein than that in the aorta, 
revealing a renal production of L-ornithine by dog kidneys (Fig. 2; Wilcoxon, P < .005). As 
previously reported, the kidneys of rats [51] and dogs [52] produce L-serine. Our results 
confirm that L-serine synthesis occurred in the dog kidney inasmuch as the plasma 
concentration of L-serine was significantly enhanced by 85 ± 31 µmol/L in the renal vein 
(Wilcoxon, P < .005). L-serine might originate in part from the disappearance of 40 ± 16 
µmol/L L-glycine from the arterial plasma (Wilcoxon, P < .005). The results also indicated 
that L-glutamine was highly consumed in the dog kidney, whereas high amounts of L-
glutamate were released (Wilcoxon, P < .005 in both cases). Interestingly, the dog kidney is an 
important source of L-alanine since its plasma concentration in the renal vein was abruptly 
increased by 353 ± 56 µmol/L (Wilcoxon, P < .005) compared with the arterial plasma. In 
addition, the V-A differences in L-taurine, L-threonine, L-asparagine, L-cystine, L-tyrosine, L-
phenylalanine, L-lysine, and L-histidine concentrations were small and significantly positive 
suggesting a release/production from the dog kidney. Given that rat and mouse kidneys express 
cysteine sulfinate decarboxylase, the rate-limiting enzyme that forms L-taurine [53], our 
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results suggest that the dog kidney might also synthesize L-taurine and express cysteine 
sulfinate decarboxylase. Concerning the low but significant release of other L-amino acids in 
the renal vein, it is conceivable that these L-amino acids originated from a significant 
catabolism of plasma proteins or peptides in the PTs [54]. 
 
3.2. Expression of enzymes involved in L-arginine anabolism in the dog renal cortex 
This experiment was performed to know whether the renal cortex of dogs expresses ASS and 
ASL proteins. Given that ASS and ASL are cytosolic enzymes, the cytosolic fraction of the 
dog cortex was purified by differential centrifugation and isolated mitochondria were used as 
negative control. Given that the antibodies used were not directed against the dog enzymes, 
identification of ASS and ASL was based on the homology of amino acid sequences between 
species. Dog mitochondria were characterized by aconitase (85 kDa) which is strictly located 
in the mitochondrial matrix (Fig. 3). The purity of the preparation was shown by the lack of 
aconitase in the cytosolic fraction (Fig. 3). The results clearly revealed that the expression of 
ASS and ASL proteins was restricted to the cytosolic fraction of the dog cortex (Fig. 3). Their 
molecular weights correponded approximatively to the predicted size of 44.3 kDa for dog ASS 
(National Center for Biotechnology Information [NCBI]: XP_537813) and 51.7 kDa for dog 
ASL (NCBI : XP_536832). The antibodies raised against the mouse ASS (NCBI : 
NP_031520) and rat ASL (NCBI : NP_067588) proteins well recognized the dog proteins. 
 
3.3. Catabolism of L-arginine in different nephron segments 
3.3.1. Proximal tubules.  
All the metabolic processes presented below were linear for at least 60 minutes (Fig. 4), 
allowing the presentation of data as metabolic rates in Table 2. In the absence of substrates, the 
PTs used endogenous L-alanine, L-aspartate, and L-glutamate (≈12 µmol/[h g wet weight)] 
and probably other endogenous L-amino acids such as L-arginine with regard to the low 
production of urea (Table 2, line 1). A small fraction of these L-amino acids were 
neoglucogenic because glucose accumulated (≈3 µmol/[h g wet weight)], whereas the main 
fraction was oxidized to support the production of energy. Indeed, the high production of NH4+ 
indicated that L-amino acids were first desaminated before being catabolized and suggested 
that oxidation was the predominant metabolic pathway at play. 
 
In the absence of exogenous L-arginine, the isolated tubules produced a very low amount of 
urea that was probably due to the intracellular storage of L-arginine. Indeed, the renal cortex of 
rats and rabbits contains higher levels of L-arginine than the blood and the other renal zones 
[55,56]; and PCT cells reabsorb the filtered amino acids including L-arginine [54,57]. In 
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contrast, incubation of suspension cortical tubules with L-arginine led to a stoechiometric and 
reciprocal disappearance of L-arginine (P < .001) and production of urea (P < .001) (Table 2, 
line 2; Fig. 4A). The presence of exogenous substrates (lactate + pyruvate or L-glutamine + L-
glutamate) did not affect this process. Quantitation of L-ornithine by ninhydrin demonstrated a 
net accumulation of L-ornithine (P < .001), but not the amount predicted from L-arginine 
disappearance and urea production, suggesting further metabolism of L-ornithine (Table 2, line 
2; Fig. 4B). The compound detected by the ninhydrin colorimetric method was also analyzed 
by HPLC to identify the L-amino acids arising from the degradation of L-arginine (Fig. 1). The 
HPLC analysis demonstrated a net accumulation of L-ornithine (retention time [RT], 11.91 
minutes) but no L-proline (RT, 5.94 minutes) in the presence of L-arginine (RT, 5.34 minutes). 
In addition, a small peak corresponding to L-glutamate-γ-semialdehyde (RT, 11.51 minutes) 
was also observed (data not shown). Because the exogenous L-arginine was metabolized into 
L-ornithine and urea, the present data strongly support that an arginase activity was expressed 
in the cortical tubules and more probably in the cortical PTs (85% PTs). 
 
The partial catabolism of L-ornithine-derived from L-arginine was confirmed by the metabolic 
effects observed in presence of L-arginine as sole substrate : a net accumulation of L-glutamate 
(P < .004) with secondary modest inhibition of glutaminase activity (EC, 3.5.1.2), leading to a 
net reduction of ammonia production (P < .003) when no lactate could stimulate ammonia 
incorporation into L-glutamate (Table 2, line 2). A stimulation of L-alanine accumulation (P < 
.001) arising from the change in tissue L-glutamate content was also observed, specially in 
presence of a source of lactate + pyruvate (Table 2, line 4). The presence of L-arginine as a 
source of L-glutamate enhanced L-alanine accumulation. No change in L-aspartate metabolism 
was noted. These observations indicate a metabolism of L-ornithine through L-glutamate 
formation (P < .004), occurring at a slower rate than the arginase flux (urea and L-ornithine 
accumulation). Glucose production was slightly inhibited by the presence of L-arginine (P < 
.015). 
 
Only the analysis of the main effects analyzed by ANOVA are presented on Table 2. Indeed, 
the interactions found were fully expected: (1) the accumulation of glucose, ammonia, and L-
glutamate as well as the uptake of substrates are different with the type of substrate used, 
leading to interactions (P < .0001) between the factors incubation time and substrates; (2) 
accumulation of L-alanine was more marked in presence of lactate (source of pyruvate) and of 
L-arginine (source of L-glutamate) than in absence of lactate, leading to an interaction between 
the factors substrates and cationic amino-acids; and (3) the effect of L-arginine was slightly 
more marked at the period 60 to 120 minutes than that during the 0 to 60 minutes, leading to 
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interactions (P < .0001) between the factors incubation time and cationic amino  acids factors 
for urea, L-ornithine, L-glutamate, and L-alanine. The F value of these interactions was 
considerably less than that calculated for the main effects. 
 
The incubation of cortical tubules with increasing amounts of L-arginine led to a progressive 
increment in urea production of up to 1 to 2 mmol/L L-arginine. Beyond 2 mmol/L L-arginine, 
the rate of urea production was significantly inflected and reduced (Fig. 5). It can be estimated 
that 1 g of kidney cortex is capable of producing 40 µmol of urea and 40 µmol of L-ornithine 
per 30 minutes under maximal conditions (10 mmol/L L-arginine) and around 5 µmol of urea 
per 30 minutes under physiological conditions (100 µmol/L L-arginine). If we consider that the 
cortical suspension contains approximately 85% PTs and 1 millimeter rat PCT is equivalent to 
0.18 µg protein [58], it can be deduced that dog PTs produced about 196 fmol urea / ornithine 
per minutes per millimeter. 
 
3.3.2. Thick ascending limbs.  
Because the production of urea and AII activity is extremely low in the rat, mouse, cat, and 
Meriones shawii MTAL [34], the suspension of dog MTAL was incubated for 60 and 120 
minutes to enhance L-arginine catabolism and the amount of urea produced. In the absence of 
substrates, extremely low levels of urea were detected, whereas the net production of NH4+ 
proved that endogenous L-amino acids were desaminated probably before being oxidized to 
sustain ATP production (Table 3, line 1). This process was decreased when adding lactate + 
pyruvate to the incubating medium (Table 3, line 3). Incubation of MTAL with 2 mmol/L L-
arginine revealed that a very small amount of L-arginine was hydrolyzed with regard to the 
production of urea (Table 3, line 2). This process was not modified by the presence of 
exogenous metabolic substrates (lactate + pyruvate). These results suggest that MTALs 
express a very low arginase activity. 
 
3.3.3 Papillary collecting ducts.  
In 2 experiments, the suspensions of dog PCDs were incubated for 120 minutes for the same 
reason as described for MTALs. Incubation of PCDs with L-arginine led to no significant 
hydrolysis of L-arginine and no production of urea either in the absence or in the presence of 
glucose as substrate (data not shown). These results suggest that PCDs probably do not express 
arginase gene. 
 
3.4. Expression of enzymes catabolizing L-arginine and L-ornithine in the dog renal cortex 
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Proteins of the renal cortex were analyzed by Western blot to prove that AII and OAT were 
expressed in dogs. The cytosolic and mitochondrial fraction of the dog renal cortex were 
separated by differential centrifugation. Mitochondria isolated from the outer stripe of the 
outer medulla of the female rat were used as a positive control because AII and OAT proteins 
are highly expressed in this renal zone [49]. As noted above and for the same reason, 
identification of the enzymes was based on the homology of amino acid sequences between 
species. As shown in Fig. 6, rat and dog mitochondria were characterized by the α-subunit F1-
ATP synthase (55 kDa), which is attached on the inner side of the inner membrane of the 
mitochondria. The lack of α-subunit F1-ATP synthase in the cytosolic fraction proved the 
purity of the preparation. As expected, AII and OAT proteins were highly expressed in the rat 
mitochondria. On this basis, our results reveal that the renal cortex of dogs expressed AII (38 
kDa) and OAT (48 kDa) proteins in the mitochondrial compartment. The molecular sizes of 
dog AII (NCBI : XP_866822 and XP_537488) and dog OAT (NCBI : XP_866064 and 
XP_535050) were similar to those found for the rat (NCBI  NP_062041 and NP_071966; 
respectively). The antibodies raised against mouse and rat OAT and AII proteins well 
recognized the dog proteins, confirming the high level of identity between their amino acid 
sequences (CLUSTALW multiple alignment, AII : 84.5% identity and OAT : 90.2 % identity). 
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DISCUSSION 
 
The basic amino acids L-arginine and L-ornithine are of central importance in the catabolic 
and biosynthetic pathways as well as in physiological events in living cells and organisms. L-
arginine is nutritionally indispensable, serves for protein synthesis, and plays a number of 
critical physiological roles, including its participation in the production of nitric oxide, 
polyamines, creatine, and L-amino acids. Therefore, L-arginine homeostasis is balanced 
between its synthesis, consumption, and degradation. 
 
In mammalian kidneys, L-arginine production requires L-citrulline and the enzymes ASS and 
ASL. However, in cats, which highly express ASS and ASL in their PTs [21], a faint synthesis 
of L-citrulline from L-glutamine and L-glutamate was due to the very low activities of OAT, 
carbamoyl phosphate synthase (EC 6.3.4.14), pyrroline-5-carboxylate synthase, and ornithine 
carbamoyl transferase (EC 2.1.3.3) in the enterocytes of their small intestine [59]. 
Consequently, the low level of L-citrulline in cat blood is incapable of sustaining an adequate 
production of L-arginine in the kidney to maintain L-arginine homeostasis [21]. In contrast, the 
dog arterial plasma exhibited high levels of L-citrulline 63 ± 5 µmol/L [this article], 48.8 ± 8.1 
µmol/L [60], 64 µmol/L [61], and 30.8 µmol/L [15] compared with those of the cats. Given 
that the renal production of L-arginine is proportional to the level of L-citrulline [13,62], the 
plasma concentrations of L-citrulline in dogs are sufficient to sustain a significant production 
of L-arginine for body needs as known in other species [13,14,16-18]. L-arginine anabolism 
also depends on the level of ASS and ASL gene expression. Nevertheless, this point has never 
been documented in the dog kidney. For the first time, we prove that ASS and ASL were 
expressed in the cytosolic fraction of the dog renal cortex by identifying their proteins on 
immunoblots. Based on their molecular weight and immunological properties, the dog ASS 
and ASL proteins strongly resemble those of the mouse and rat as confirmed by the high level 
of identity between their amino acid sequences (CLUSTALW multiple alignment: ASS, 92.9% 
identity and AS, 88.6% identity, respectively). Although the localization of ASS and ASL 
proteins were not performed in a suspension of dog PTs, it is known that the PTs are the most 
abundant tubules in the cortex [58,63] and both enzymes are essentially expressed in the PCT 
of several species [20,23]. Moreover, the PCT is the privileged site of L-citrulline reabsorption 
[64]. Altogether, this study proves that under normal physiological conditions, the dog kidney 
extracted L-citrulline from the arterial blood (-16 ± 4 µmol/L) and, statistically, released equal 
amounts of L-arginine into the renal venous blood (+22 ± 4 µmol/L). Mongrel dogs and beagle 
exhibited high and quite similar arterial plasma concentration of L-arginine (141 ± 8 µmol/L 
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[60] and 163 ± 9 to 177 ± 12 µmol/L [15] for the former and 124 ± 12 µmol/L for the latter 
[this study]). Noticeably, the sum L-arginine plus L-ornithine released in the renal vein is 
higher than L-citrulline consumed in the kidney. Several reasons are listed to explain this 
discordance : (1) Protein catabolism occurs in the dog kidney, and the molecules of L-arginine 
incorporated into proteins might be a source of L-arginine and L-ornithine derived from L-
arginine catabolism. This point is supported by the data from Yu et al. [15] who reported that  
the total L-arginine released from the kidney (19 µmol/[kg h]) exceeded the 6.8 µmol/(kg h) 
that was formed from L-citrulline and released into the renal vein. (2) Methylation of L-
arginine residues of protein produces NG-monomethylarginine, NG,NG-dimethylarginine 
(asymmetrical dimethylarginine); and NG,N’G-dimethylarginine (symmetrical 
dimethylarginine). Proteolysis of proteins releases free NG-monomethylarginine and 
asymmetrical dimethylarginine, which are metabolized into methylamines and L-citrulline by 
NG,NG-dimethylarginine dimethylaminohydrolase (EC 3.5.3.18) [65]. Given that NG,NG-
dimethylarginine dimethylaminohydrolase is expressed in PTs, the bulk of L-citrulline 
produced locally might be an additional source of L-arginine [66]. (3) Ornithine 
aminotransferase catalyzes a reversible reaction that leads to either L-glutamate or L-ornithine. 
At present, we do not know how the renal OAT of dogs works in vivo. It cannot be excluded 
that OAT produces L-ornithine from L-glutamine and L-glutamate. 
 
Although several enzymes control L-arginine catabolism in the kidney, our attention was 
restricted to AII. In PTs, the substrate L-arginine can be endogenously produced from L-
citrulline or can enter the cells at least by the apical membrane of the rat PT (reabsorption) 
[67]. To prevent the endogenous production of L-arginine, suspensions of tubules were 
incubated without L-citrulline. In the presence of exogenous L-arginine, PTs produced a high 
amount of urea that was accompanied by an equimolar diminution of L-arginine and a nearly 
equimolar accumulation of L-ornithine. Given that the renal arginase is localized in 
mitochondria [35,68,69], our data support that L-arginine was also transported into 
mitochondria to be further metabolized. Our results showed that PTs expressed a high arginase 
activity compared with MTALs, whereas PCDs did not express this enzyme. The expression of 
an AII was clearly confirmed by analyzing on immunoblots mitochondrial proteins isolated 
from of the dog cortex (> 85% PTs). Our results are in a good agreement with the report of 
Rabinowitz et al [70] that depicted an arginase activity almost exclusively in the renal cortex. 
Unfortunately, in our study, we omitted to test whether proximal straight tubules express an 
arginase activity. The distribution pattern of AII within the dog kidney strongly differs from 
those of rats and mice [33,71], but exhibits a similarity with those of rabbits, guinea pigs, cats, 
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and Meriones shawii, which expressed an arginase in their PCT [21,33,34]. The data obtained 
in dogs sustain the view that the renal distribution of AII is species specific. Given that the 
amino acid sequence of the dog AII (NCBI : XP_866822 and XP_537488) contains the 
IASSFGQTREGGHIVYD peptide sequence that shows 87.5% identity with the 
IASSFGQTREGGHIEC peptide sequence used to prepare our primary antibody and that a 
molecular weight of 38 kDa was found for the dog arginase in mitochondria, the dog AII might 
strongly resemble those of mice [35] and rats [49]. 
 
Interestingly, in cells, several metabolic pathways are interconnected; and the presence or the 
absence of exogenous metabolites might modify the homeostasis of the end-product of these 
pathways. This is why we examined the metabolic consequences of L-arginine hydrolysis in a 
suspension of dog cortical PTs to integrate AII activity into a general physiological and 
metabolic framework. The metabolic behaviour of L-arginine was analyzed in detail to give an 
insight to (1) the metabolic fate of L-ornithine-derived from L-arginine hydrolysis and (2) the 
interaction between L-arginine catabolism and metabolites such as lactate and L-glutamine 
known to be also highly metabolized in this nephron segment (Fig. 1) [72,73]. In cortical PTs, 
the rate of L-arginine hydrolysis apparently exceeded that of L-ornithine appearance because 
L-ornithine accumulation in the incubating medium corresponded to 76 to 85% of the amount 
of L-arginine hydrolyzed. In addition, we observed that the plasma concentration of L-
ornithine was higher in the renal vein than that in the aorta, indicating that the dog kidney 
released L-ornithine in the bloodstream. We calculated that the dog PT produced about 282 
nmol of L-ornithine per millimeter per day. This value is dramatically higher than the values 
found for the PCT of cats [21], guinea pigs [34], rabbits [33], and Meriones shawii [34]. 
Consequently, we proposed that, in the dog kidney, the function of AII might be to supply 
circulating L-ornithine for the body. Release of L-ornithine from the kidney has been also 
observed in humans [18]. 
 
The remaining 15% to 24% of L-ornithine derived from L-arginine can serve as precursor for 
putrescine, L-proline, and L-glutamate synthesis or can be oxidized to supply ATP for cellular 
functions. It is generally assumed that L-proline synthesis cannot occur in the kidney because 
the enzyme pyrroline-5-carboxylate reductase (EC 1.5.1.2) that converts 1-pyrroline-5-
carboxylate into L-proline is lacking. Our HPLC chromatogram clearly confirmed the lack of 
L-proline production by dog PTs (data not shown). The expression of ODC that converts L-
ornithine into putrescine remains undocumented in dog kidney. In contrast, L-ornithine can be 
transaminated by OAT (Fig. 1). However, given that the concentration of L-ornithine 
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generated from L-arginine by AII is fairly small, the rate of L-ornithine transamination in the 
dog cortical PTs occurred at a relatively low rate. The identification of glutamate-γ-
semialdehyde by HPLC in PTs incubated with L-arginine supported the view of L-ornithine 
transamination. Moreover, the existense of this pathway is strongly supported by revealing the 
expression of OAT protein in the dog renal cortex on immunoblots. The molecular weight of 
the dog OAT (48.3 kDa) was similar to that of the female rat [49]. In addition, the amino acid 
sequence of the dog OAT (NCBI : XP_866064 and XP_535050) contains the 3 peptide 
sequences (SVATKKTIQGPPSSDY, IFERESKYGAHYHP, and IMLTIKAGEHGSTYG) that 
exhibited 87.5%, 100%, and 92.8% identity, respectively to the 3 peptide sequences 
(SVATKKEQGPPSSEC, IFERESKYGAHNYHC, and CMLTIKPGEHGSTYG) used to 
prepare our primary OAT antibody. 
 
The interaction between L-arginine catabolism and other metabolites is discussed in this 
section. The presence of L-arginine in the incubating medium modified L-glutamine 
metabolism in PTs. L-glutamine utilization (-84.5 vs -71.4 = 13.1) and NH4+ production (136 
vs 112 = 24) were significantly reduced, whereas L-glutamate accumulation was significantly 
increased (25.4 vs 28.6 = 3.2). Under our incubating conditions, NH4+ originated from L-
glutamine, L-glutamate, and L-amino acids produced during protein catabolism. In the 
presence of L-arginine, the decrease in NH4+ production was about twice greater than that 
expected from L-glutamine utilization. To explain this result, we propose that L-arginine 
provoked a weak inhibition of phosphate-dependent glutaminase (EC 3.5.1.2) and glutamate 
dehydrogenase (EC 1.4.1.2) activities by an unknown mechanism. These 2 mitochondrial 
enzymes are involved in L-glutamine and L-glutamate catabolism and are expressed in the PT 
[72,74,75]. Interestingly, AII and OAT are also localized in the mitochondrial matrix 
[35,49,68,69] and in the dog PT. To explain the concomitant decrease in L-glutamine 
utilization and L-glutamate accumulation, we hypothesized that a fraction of L-glutamate 
originated from the transamination of L-ornithine derived from L-arginine by OAT activity. In 
addition, the production of glutamate-γ-semialdehyde during the transamination step controlled 
by OAT might serve to produce a second molecule of L-glutamate (Fig. 1). Given that L-
glutamate is known to be the most important inhibitor of kidney-type glutaminase [72], L-
glutamate generated by OAT could negatively regulate phosphate-dependent glutaminase 
activity in the mitochondria. 
 
Regarding the metabolic fate of L-glutamate produced by OAT, this amino acid serves either 
to synthesize L-glutamine or to regenerate α-ketoglutarate for another transamination step. The 
synthesis of L-glutamine is controlled by the enzyme glutamine synthetase (EC: 6.3.1.2) that is 
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expressed in the PT of the rat and rabbit kidneys [76]. In contrast to these species, the dog 
kidney does not express glutamine synthetase [77]. Consequently, the alternative route for L-
glutamate is to undergo deamination by glutamate dehydrogenase to produce α-ketoglutarate 
that can be (1) completely oxidized in the Krebs cycle to supply energy for the cells, (2) used 
to transaminate a new molecule of L-ornithine, (3) used by aspartate transaminase (EC 2.6.1.1) 
and alanine aminotransferase (EC 2.6.1.2), or (4) recycled for gluconeogenesis (Fig. 1). 
Although the carbons of α-ketoglutarate can lead to the production of oxaloacetate and then to 
glucose in the gluconeogenic pathway, the carbons of L-ornithine derived from L-arginine did 
not contribute to glucose synthesis because the presence of L-arginine produced a modest 
inhibition of glucose synthesis in the presence of exogenous L-glutamine or lactate. This may 
be related to the increased level of L-glutamate modulating the intramitochondrial-limiting 
oxaloacetate concentration. The fact that L-alanine (with lactate) production was increased by 
L-arginine suggested that the increased in L-glutamate level was responsible for this finding, 
presumably through increased utilization of pyruvate towards amino acid synthesis. In the dog 
kidney, L-arginine is therefore not a major gluconeogenic L-amino acid. 
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FIGURE   LEGENDS 
 
Fig. 1 Relationship between the metabolic pathways of L-arginine, L-ornithine, and other 
amino acids; the Krebs cycle; and the gluconeogenesis pathway in dog cortical PTs. 
Enzymes are written in red, and the metabolites measured are written in green. In the 
Krebs cycle and gluconeogenesis, only the essential enzymatic steps are indicated. 
The red cross indicates that GS is not expressed in the dog kidney. The expression of 
ODC in the dog cortex is still unknown (dashed line). ALAT (EC 2.6.1.2) indicates 
alanine aminotransferase or alanine transaminase; α-kGDH (EC 1.2.4.2), α-
ketoglutarate dehydrogenase; AspT (EC 2.6.1.1) aspartate transaminase; CS (EC 
2.3.3.1), citrate synthase; GLDH (EC : 1.4.1.2) glutamate dehydrogenase; GS (EC 
6.3.1.2) glutamine synthetase; LDH (EC 1.1.1.27) lactate dehydrogenase, PC (EC : 
6.4.1.1), pyruvate carboxylase; PDG (EC : 3.5.1.2), phosphate dependant 
glutaminase; PEPCK (EC :4.1.1.49), phosphoenolpyruvate carboxykinase; P5C-R 
(EC : 1.5.1.2), 1-pyrroline-5-carboxylate reductase; P5C-DH (EC : 1.5.1.12), 1-
pyrroline-5-carboxylate dehydrogenase; PDH (EC : 1.2.1.51), pyruvate 
dehydrogenase; PK (EC : 2.7.1.40), pyruvate kinase. 
 
Fig. 2  Individual plasma concentrations of L-citrulline, L-arginine, and L-ornithine in the 
renal vein and aorta in the 5 dog studied. 
 When the concentration of plasma L-amino acid is higher in the aorta (closed square) 
than that in the renal vein (open square), the kidney extracted and metabolized the L-
amino acid considered. In contrast, when the concentration of plasma L-amino acid is 
lower in the aorta than that in the renal vein, the kidney released and produced the L-
amino acid considered. Detail : for L-ornithine, 2 dogs had similar concentrations in 
the aorta and renal vein. 
 
Fig. 3 Expression of ASS and ASL in the dog cortex. 
The cytosolic fraction and isolated mitochondria were purified by differential 
centrifugation. Two hundred micrograms of dog cytosolic and mitochondrial (used as 
negative control) proteins were subjected to 9% SDS-PAGE containing 0.1% SDS 
and analyzed by Western blotting. Each antibody (ASS, ASL, and aconitase) was 
incubated alone with the immunoblot. After rinsing, the immunoblot was incubated 
with the peroxidase-conjugated anti-rabbit IgG secondary antibody. Binding was 
revealed by ECL, and luminescence was monitored on X-ray films. Aconitase was 
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used as marker of mitochondria. Cyto indicates cytosolic fraction; Mito, 
mitochondria. 
 
Fig. 4  Urea (A) and L-ornithine (B) production as a function of the incubation time. 
 Suspensions of dog cortical tubules composed of more than 85% PTs were incubated 
with 2 mmol/L L-arginine in absence (closed squares) or presence of exogenous 
substrates (2 mmol/L lactate + 0.2 mmol/L pyruvate [open circles] or 2 mmol/L L-
glutamine + 0.2 mmol/L L-glutamate [closed circles]). Data are expressed as means ± 
SE; n = 4 experiments. The metabolic processes were linear for at least 60 minutes. 
 
Fig. 5 Dose-response curve of urea production as a function of L-arginine concentration. 
Suspensions of dog cortical tubules composed of more than 85% PTs were incubated 
with increasing concentrations of L-arginine (0-10 mmol/L) for a period of 30 
minutes to prevent a sharp disappearance of L-arginine. Data are expressed as means; 
n = 2 experiments. 
 
Fig. 6 Expression of AII and OAT in the dog cortex. 
Mitochondria were separated from the cytosolic fraction by differential centrifugation. 
Two hundred micrograms of dog cytosolic and mitochondrial proteins and rat 
mitochondrial proteins (used as positive control) were subjected to 9% SDS-PAGE 
containing 0.1% SDS and analyzed by using Western blot. Each of the following 
antibody was incubated alone with the immunoblot: AII, OAT, and α-subunit F1-ATP 
synthase. After rinsing, the immunoblot was incubated with the appropriate 
peroxidase-conjugated anti-rabbit or anti-mouse IgG secondary antibody, revealed by 
ECL, and exposed to x-ray film. The α-subunit F1-ATP synthase were used as marker 
of the mitochondrial fraction. 
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